1. "DMHA is a dietary ingredient" vs "DMHA is not a dietary ingredient"

Manufacturer claim (2014-2019 era): DMHA / 2-aminoisoheptane / octodrine has historical pharmaceutical use (1950s Vaporpac), constitutes a "dietary ingredient" under DSHEA, and can be marketed in dietary supplements.

FDA position (April 2019 enforcement, ongoing): DMHA is NOT a dietary ingredient because (a) it lacks a documented pre-1994 marketing record as a dietary supplement / food (DSHEA "grandfather" status), and (b) it lacks a New Dietary Ingredient (NDI) notification submitted to FDA. Products containing DMHA are therefore subject to FDA enforcement under the FD&C Act as adulterated dietary supplements.

Reality check: The FDA position is the prevailing regulatory reality in the US. DMHA cannot legally be sold in dietary supplements. The historical Vaporpac / octodrine medical use is irrelevant to the dietary-ingredient question — it does not establish DSHEA grandfather status, which requires pre-1994 marketing as a dietary supplement specifically.

My read: FDA position is correct on the regulatory question. Manufacturer position was a transparent attempt to thread a needle in DSHEA between "this is a drug" and "this is a food." DMHA's history is pharmaceutical (1950s octodrine), then abandoned, then resurrected in 2014 as a designer pre-workout ingredient — none of that establishes it as a dietary supplement under DSHEA.

2. DMHA vs DMAA — same compound, different compound, or class-equivalent?

Background: DMAA (1,3-dimethylamylamine, methylhexanamine, "geranamine") is a 6-carbon secondary amine; DMHA (2-aminoisoheptane, octodrine) is a 7-carbon primary amine. They are not identical, but they are in the same aliphatic-amine sympathomimetic class.

The supplement industry framing (2014-2019): "DMHA is a different compound, with its own evidence base, not subject to the DMAA ban."

Pharmacological reality: The two compounds share the aliphatic-amine sympathomimetic mechanism class and the same general hazard signal (CV elevation, sympathetic load, dose-dependent stimulation). They are not pharmacologically interchangeable in detail, but they are class-equivalent for safety / regulatory purposes.

My read: The "DMHA is different from DMAA" framing was technically accurate but practically misleading. Both compounds belong to the same regulatory hazard class, and FDA's 2019 enforcement against DMHA followed the same logic as the 2013 enforcement against DMAA. The industry's pattern of cycling through structurally-related "DMAA replacements" (DMAA → DMHA → 1,3-DMBA → AMP citrate → ...) is a regulatory cat-and-mouse pattern, not innovation.

3. DEA scheduling question

Common community misunderstanding: "DMHA is banned" → assumed to be a Schedule I-V controlled substance.

Reality: DMHA is NOT DEA-scheduled. It is not a controlled substance under the CSA. The "ban" is FDA enforcement against use in dietary supplements, not DEA scheduling. DMHA is not personally illegal to possess in the US — it is illegal to sell as a dietary supplement.

Implications: This is similar to DMAA (also FDA-enforcement, not DEA-scheduled) and unlike SARMs (where the SARMs Control Act 2014 attempted DEA scheduling via the Designer Anabolic Steroid Control Act / DASCA mechanisms — though SARM-specific scheduling has been legally complex). DMHA's regulatory posture is purely FDA / FD&C Act / DSHEA — not CSA.

My read: Important to get right because the legal posture matters: a tested athlete or employee facing a workplace drug screen needs to know that DMHA can show up on a stimulant-class urine screen even though it's not a "controlled substance," and that buying it is not DEA-illegal even though selling it as a supplement is FDA-non-compliant.

4. SARMs Control Act 2014 / DASCA relevance

Common community misunderstanding: "DMHA was affected by SARMs Control Act / DASCA."

Reality: SARMs Control Act 2014 + DASCA target anabolic steroids and SARMs. DMHA is neither a steroid nor a SARM — it is an aliphatic amine sympathomimetic. SARMs Control Act / DASCA did NOT affect DMHA.

My read: Important regulatory clarification. DMHA's enforcement posture is entirely FDA / FD&C Act / DSHEA "not a dietary ingredient" — not CSA, not SARMs Control Act, not DASCA.

5. Cohen et al. data quality + the case for FDA enforcement

Background: Cohen et al. (Pieter Cohen / Boston / Cambridge Health Alliance) is the canonical research group documenting designer-supplement adulteration and undisclosed-ingredient detection. Cohen 2018 detected DMHA in pre-workouts at 73-271 mg per scoop with high inter-product variance; Cohen 2019 (J Med Toxicol) reviewed the cardiovascular hazard signal.

Critique from supplement industry: "Cohen's research is biased / activist." This critique has been raised but has not diminished the regulatory / legal weight of the analytical detection data — the chemistry is reproducible and FDA accepts it.

My read: Cohen's group is doing the unglamorous work of supplement-supply-chain QC that the supplement industry refuses to self-perform. The detection data is the basis of FDA's 2019 enforcement action and is methodologically robust. The industry critique is special pleading.

6. Vaporpac / octodrine historical medical use

Background: Octodrine (the same molecule as DMHA / 2-aminoisoheptane) was marketed in the 1950s under the brand "Vaporpac" as an inhaled nasal vasoconstrictor / decongestant — basically a more aggressive analog of pseudoephedrine.

Implications:

• The medical use was specifically as a topical / inhaled vasoconstrictor for nasal congestion, not as a systemic stimulant
• The dose, duration, and indication were entirely different from modern pre-workout use
• The product was abandoned by the 1960s in favor of better-characterized agents (xylometazoline, oxymetazoline, pseudoephedrine)
• The 1950s medical use does NOT establish DSHEA grandfather status for dietary-supplement marketing
• The 1950s safety / efficacy data is not reanalyzed to modern methodology and would not satisfy current FDA standards for any indication

My read: The "DMHA has medical history, therefore it should be allowed in supplements" argument fails on multiple grounds. The medical history is real but irrelevant to the DSHEA dietary-ingredient question, and the medical product was specifically a topical vasoconstrictor, not a systemic stimulant.

7. "DMHA is safer than DMAA" claim

Manufacturer / community claim: DMHA is "smoother / cleaner / safer" than DMAA.

Reality check: Cohen 2019 documented the same general cardiovascular hazard pattern in DMHA-containing products that drove the DMAA ban. The "smoother" subjective feel is consistent with slightly different PK (longer half-life, less pulsatile peak), but the underlying class-level hazard is the same. There is no published evidence that DMHA has a meaningfully better safety profile than DMAA.

My read: Marketing claim, not validated. Class-level safety concerns are equivalent between DMAA and DMHA.